ENANTA PHARMACEUTICALS, INC Restricted Cash and Cash Equivalents
ENANTA PHARMACEUTICALS, INC (ENTA) had Restricted Cash and Cash Equivalents of $436.00 thousand as of 2013-09-30, per its 10-K filed 2013-12-18.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2013-12-18
- 2013-09-30: Restricted Cash and Cash Equivalents $436.00K.
- 2013-06-30: Restricted Cash and Cash Equivalents $436.00K.
- 2013-03-31: Restricted Cash and Cash Equivalents $436.00K.
- 2012-09-30: Restricted Cash and Cash Equivalents $436.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2013-09-30 | $436.00K 10-K · filed 2013-12-18 |
| 2013-06-30 | $436.00K 10-Q · filed 2013-08-12 |
| 2013-03-31 | $436.00K 10-Q · filed 2013-05-15 |
| 2012-09-30 | $436.00K 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |